ASX ANNOUNCEMENT **29 May 2024**

Cynata Presenting at Major International Cell Therapy Conference

Melbourne, Australia; 29 May 2024: Cynata Therapeutics Limited (ASX: "**CYP", "Cynata",** or the **"Company"**), a clinical-stage biotechnology company specialising in cell therapeutics, will participate by invitation in the International Society of Cell and Gene Therapy (ISCT) Annual Meeting in Vancouver, Canada.

At 10:45am local time[1] on Wednesday 29 May, Dr Kilian Kelly, Cynata's Chief Executive Officer and Managing Director, will take part in a panel discussion on "*Back to the Future: Setting up MSC Clinical Trials for Success*".

At 1:45pm local time on Saturday 1 June, Dr Kelly will present on the clinical development of Cynata's Cymerus™ off-the-shelf iPSC[2]-derived MSC[3] products, as part of the *iPSC Scientific Signature Series*. A copy of the presentation is attached.

Established in 1992, the ISCT is a global society of clinicians, regulators, researchers, technologists, and industry partners with a shared vision to translate cell and gene therapy into safe and effective therapies to improve patients' lives worldwide. The ISCT annual meeting is expected to be attended by over 2,500 delegates.

Further information on the event can be found at the following link:
https://www.isctglobal.org/isct2024/home

-ENDS-

Authorised for release by Dr Kilian Kelly, CEO & Managing Director

CONTACTS: Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, kilian.kelly@cynata.com
Lauren Nowak, Media Contact, +61 (0)400 434 299, littlebigdealconsulting@gmail.com

About Cynata Therapeutics (ASX: CYP)
Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. A Phase 2 clinical trial in GvHD under a cleared US FDA IND, as well as trials of Cymerus products in osteoarthritis (Phase 3) and diabetic foot ulcers (DFU) are currently ongoing, while a trial in renal transplant is expected to commence in the near future. In addition, Cynata has also demonstrated utility of its Cymerus technology in preclinical models of numerous diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.

[1] Dates and times are in Pacific Daylight Time (UTC -7)
[2] iPSC = induced pluripotent stem cell
[3] MSC = mesenchymal stem (or stromal) cell

cynata therapeutics



Cymerus™ iPSC-derived MSCs – Clinical Development in Multiple Therapeutic Areas

Kilian Kelly, PhD

Chief Executive Officer and Managing Director

1 June 2024

ISCT 2024

VANCOUVER, CANADA

MAY 29 – JUNE 1

Important information

Summary information

This Presentation contains summary information about Cynata Therapeutics Limited and its subsidiaries (**CYP**) which is current as at 28 May 2024. This Presentation should be read in conjunction with CYP's other periodic and continuous disclosure information lodged with the Australian Securities Exchange (**ASX**), which are available at www.asx.com.au.

Not an offer

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with the ASIC) or any other law. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The release, publication or distribution of this Presentation (including an electronic copy) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions. Any non-compliance with these restrictions may contravene applicable securities laws.

Not investment advice

This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation by CYP or its advisers to acquire CYP securities. This Presentation has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. CYP is not licensed to provide financial product advice in respect of CYP securities.

Investment risk and past performance

An investment in CYP securities is subject to known and unknown risks, some of which are beyond the control of CYP and its directors. CYP does not guarantee any particular rate of return or performance of CYP. Past performance cannot be relied upon as an indicator of (and provides no guidance as to) future CYP performance including future share price performance.

Financial data

All financial information in this Presentation is in Australian currency (A$) unless otherwise stated. This Presentation contains historical financial information based on the Company's results for the quarter to 31 March 2024. This information is disclosed in the Appendix 4C report lodged with the ASX on 30 April 2024. Any discrepancies between totals and sums of components in tables and figures in this Presentation are due to rounding.

Forward-looking statements

This Presentation contains certain 'forward looking statements', which can generally be identified by the use of forward looking words such as 'expect', 'anticipate', 'likely', 'intend', 'should', 'could', 'may', 'predict', 'plan', 'propose', 'will', 'believe', 'forecast', 'estimate', 'target', 'outlook', 'guidance', 'potential' and other similar expressions. The forward looking statements contained in this Presentation are not guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of CYP, its directors and management, and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There can be no assurance that actual outcomes will not differ materially from these forward looking statements. A number of important factors could cause actual results or performance to differ materially from the forward looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation. The forward looking statements are based on information available to CYP as at the date of this Presentation. Except as required by law or regulation (including the ASX Listing Rules), CYP and its directors, officers, employees, advisers, agents and intermediaries undertake no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. You are strongly cautioned not to place undue reliance on forward-looking statements, particularly in light of the current economic climate and the significant volatility, uncertainty and disruption caused by the outbreak of COVID-19.

Industry and Market data

Certain market and industry data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither CYP nor its representatives have independently verified any such market or industry data provided by third parties or industry or general publications.

Disclaimer

To the maximum extent permitted by law, CYP and its advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents (**Related Persons**) exclude and disclaim all liability, including without limitation for negligence, for any expenses, losses, damages or costs arising from this Presentation or reliance on anything contained in or omitted from it. To the maximum extent permitted by law, CYP and its Related Persons make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this Presentation and disclaim any obligation or undertaking to release any update or revision to the information in this Presentation to reflect any change in expectations or assumptions. Statements made in this Presentation are made only as at the date of this Presentation. The information in this Presentation remains subject to change without notice.

Company highlights

Revolutionary iPSC-based Cymerus™ manufacturing platform

- Effectively **limitless** quantity of **consistent**, **high-quality** mesenchymal stem cell (MSC) doses from a **single blood donation**
- Overcomes major obstacle to commercialisation in this highly promising field

Compelling clinical data

- **Acute graft versus host disease (aGvHD) Phase 1:** 53% complete response; 87% overall response
- **Diabetic foot ulcer (DFU) Phase 1:** 88% median wound surface area reduction vs 51% in controls[1]

Rich clinical pipeline

- Three major randomised controlled clinical trial readouts upcoming:
  DFU (Phase 1) – early 2025; **aGvHD** (Phase 2) – 2H 2025; and **osteoarthritis** (Phase 3) – early 2026
- New trial in kidney transplantation to commence in Q2 2024

cynata therapeutics

iPSC = induced pluripotent stem cell
1. Initial data in first 16 patients (n=8 per group) after 10 weeks

Revolutionary iPSC-based Cymerus™ Manufacturing Platform



Conventional MSC process

Ongoing need for new donors

Substantial inter-donor **variability**

MSC isolation



Small number of MSCs per donation

Culture expansion

Extensive MSC culture expansion required

Major challenges:

- Logistically challenging
- Inter-donor **variability** – **inconsistent** activity in MSCs from different donors
- MSCs undergo **functional changes** during extensive culture expansion

Cymerus™ iPSC-based process

One donor, one time

Avoids inter-donor variability

Reprogramming & iPSC expansion



Effectively **limitless** Expansion potential

Differentiation into MSCs & culture expansion



Minimal MSC culture expansion

Advantages of **Cymerus** platform:

- **Effectively limitless** iPSC expansion potential
- **Avoids** need for new donors
- **Avoids** inter-donor variability
- **Avoids** need for extensive MSC expansion
- High level of **consistency**

cynata therapeutics

Therapeutic potential of MSCs



Mesenchymal stem (or stromal) cells (MSCs):

- Promote an **immunomodulatory** environment via multifactorial mechanisms[1]
- The "sensor and switcher of the immune system"[2]
- Promote **tissue repair** and **regeneration**
- Can be used **without** donor/recipient matching
- Can be **engineered** to express other functional/therapeutic molecules

1. Kelly and Rasko, Front. Immunol. 12:761616.
2. Sarsenova et al, Front. Immunol.13:1010399.

Illustration from ref #1.

Rich Clinical Pipeline – Multiple Upcoming Data Readouts



Advanced and diverse clinical pipeline



1. Global Graft versus Host Disease Market 2019-2029 (Reflects forecast market in 2026); 2. Zion Market Research, 2019 (represents global treatment market in 2025); 3. Persistence Market Research 2018 research report: "Osteoarthritis Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025) (Reflect OA market by 2025); 4. Organ Transplant Immunosuppressant Drugs Market in 2026, Grand View Research, Inc.,2019

USYD = University of Sydney; NHMRC = National Health and Medical Research Council; LUMC = Leiden University Medical Center

cynata therapeutics

Acute Graft Versus Host Disease (aGvHD)



aGvHD | Phase 1 clinical trial

Product: CYP-001 (Cymerus MSCs for intravenous infusion)

- First completed clinical trial worldwide with any iPSC-derived product
- Led to two publications in *Nature Medicine*

LETTERS
https://doi.org/10.1038/s41591-020-1050-x
nature medicine
Check for updates

Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study

Adrian J. C. Bloor[1,2] ✉, Amit Patel[1], James E. Griffin[3], Maria H. Gilleece[4], Rohini Radia[5], David T. Yeung[6,7], Diana Drier[8], Laurie S. Larson[8], Gene I. Uenishi[9], Derek Hei[10], Kilian Kelly[11], Igor Slukvin[9] and John E. J. Rasko[12,13,14] ✉

nature medicine

Brief Communication

https://doi.org/10.1038/s41591-024-02990-z

Two-year safety outcomes of iPS cell-derived mesenchymal stromal cells in acute steroid-resistant graft-versus-host disease

Received: 9 December 2023

Accepted: 10 April 2024

Published online: 22 May 2024

Kilian Kelly[1], Adrian J. C. Bloor[2], James E. Griffin[3], Rohini Radia[4], David T. Yeung[5,6] & John E. J. Rasko[7,8,9] ✉

cynata therapeutics

GvHD is a significant cause of death after HSCT



NB: GvHD may also contribute to other causes of death (e.g. infection, haemorrhage, organ failure)

CIBMTR
CENTER FOR INTERNATIONAL BLOOD & MARROW TRANSPLANT RESEARCH

Source: Bolon YT, Atshan R, Allbee-Johnson M, Estrada-Merly N, Lee SJ. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides, 2022

Overview of CYP-001 Phase 1 Clinical Trial

Protocol #	CYP-GvHD-P1-01
Clinical sites	7 (UK and Australia)
Eligibility	• Adults with Grade 2-4 SR-aGvHD • Life expectancy of at least 1 month
Study Design	Two sequential cohorts, n=8 per cohort: • Cohort A: $1x10^6$ cells/kg (max $1x10^8$ cells) by IV infusion on D0 and D7 • Cohort B: $2x10^6$ cells/kg (max $2x10^8$ cells) by IV infusion on D0 and D7
Endpoints	• Safety and tolerability (primary) • Complete/Partial Response by D28/D100 • Overall survival up to 2 years

cynata therapeutics

aGvHD | Phase 1 clinical trial - results

Product: CYP-001 (Cymerus MSCs for intravenous infusion)





- No serious adverse events, tumors or other safety concerns related to CYP-001
- Causes of death were complications commonly observed in allogeneic HSCT recipients, not considered by investigators to be related to CYP-001 treatment
- Survival rate compares favourably to other interventions – e.g. in Phase 3 trial of ruxolitinib, OS at 18 months was 38% in ruxolitinib group and 36% in 'best available therapy' group (2 year OS was not evaluable)
- CYP-001 was shown to be safe and well tolerated, with sustained outcomes up to 2 years after the first infusion

cynata therapeutics

- Subjects received $1x10^6$ cells/kg (max $1x10^8$ cells) or $2x10^6$ cells/kg (max $2x10^8$ cells) by IV infusion on D0 and D7
- Eight subjects were enrolled in each cohort, but one subject in Cohort B withdrew prior to infusion of CYP-001

‡ Subject A3 showed a PR at Days 14 and 21 but died due to pneumonia on Day 28; * Subject B5 withdrew from the trial on Day 22 to commence palliative care

aGvHD | Phase 2 clinical trial

Product	CYP-001 (Cymerus™ iPSC-derived MSCs for intravenous infusion)
Indication	High risk acute graft versus host disease (aGvHD)[1]
Study Design	• Randomised controlled trial in ~60 adults (steroids + CYP-001 vs steroids + placebo) • Primary objective is to assess efficacy of CYP-001 based on Overall Response Rate at Day 28
Study Conduct	• Clinical sites in USA, Europe and Australia • Regulatory/ethics approvals secured in Australia, USA, Turkey and EU • Numerous sites now open for recruitment, with remainder expected to open in Q2 2024 • First patient enrolled – March 2024 • Aiming to complete recruitment by end of calendar year 2024
Results	Primary evaluation results anticipated in 2H CY 2025

1. aGvHD may occur after bone marrow transplantation/similar procedures, due to donor immune cells (from the “graft”) attacking the transplant recipient (the “host”)

Diabetic Foot Ulcer (DFU)



CYP-006TK – a novel topical MSC product

- CYP-006TK utilises a proprietary surface-coating, optimised for the delivery of MSCs directly to the wound bed
- Technology exclusively licenced to Cynata by Tekcyte Limited



Preclinical study in diabetic wounds

Murine model of diabetic wounds



Key findings

- Primary outcome measure was extent of re-epithelialisation of wound surface after 3 days
- Comparator MSCs were derived using conventional manufacturing
- Cymerus MSCs resulted in significantly greater re-epithelialisation (86%) compared to bone marrow MSCs (51%)
- Although gingival fibroblasts and bone chip MSCs produced similar results, there are major challenges associated with producing clinical-grade cells from those sources at commercial scale

cynata therapeutics

Source: ASX Announcement ASX.CYP 31 May 2018 titled 'Cynata's CymerusTM MSCs Effective in Preclinical Model of Diabetic Wounds'.

DFU | Phase 1 clinical trial

Product	CYP-006TK (Novel silicone dressing seeded with Cymerus™ iPSC-derived MSCs)
Indication	Non-healing diabetic foot ulcers (DFU)
Study Design	• Randomised controlled trial in ~30 adults • Patients randomised to receive either standard of care or CYP-006TK for 4 weeks, followed by standard of care • Primary objective is safety; efficacy measures include wound healing, pain and quality of life
Study Conduct	• Clinical sites in Australia (Adelaide and Perth) • Recruitment complete (April 2024) • Last patient visit expected ~September 2024
Results	• Positive initial results from first 16 patients released Feb 2024 (see next slide) • Final results anticipated in Q4 2024 or Q1 2025

cynata therapeutics

DFU | Phase 1 clinical trial – initial data

Product: CYP-006TK (topical Cymerus MSC wound dressing)

- Ongoing trial in non-healing diabetic foot ulcer (DFU)
- Patients randomised to receive standard of care (SoC) or CYP-006TK for 4 weeks, followed by SoC
- In the first 16 patients enrolled in the trial (8 per group), after 10 weeks' follow-up, the median reduction in wound surface area was:
  - **87.6%** in the active CYP-006TK group
  - compared to **51.1%** in SoC group

Example of ulcer healing in patient treated with CYP-006TK:

Day 0



Day 28



cynata therapeutics

Osteoarthritis



OA | Phase 3 clinical trial[1]

Product	CYP-004 (Cymerus™ iPSC-derived MSCs for intra-articular injection)
Indication	Osteoarthritis (OA) of the knee (Kellgren-Lawrence Grade 2-3)
Study Design	• Randomised, double-blind placebo-controlled trial in ~320 adults • Each participant receives 3 injections over 12 months; follow-up of 24 months from first dose • Co-primary endpoints are reduction of knee symptoms and measure of cartilage loss
Study Conduct	• Trial conducted by University of Sydney, funded by Australian Government NHMRC grant • Clinical centres in Australia (Sydney and Hobart) • Recruitment complete (November 2023) • Last patient last visit expected ~November 2025
Results	• Results anticipated in H1 CY 2026

cynata therapeutics

1. Clinical trial entitled Stem Cells as a symptom – and strUcture-modifying Treatment for medial tibiofemoral OsteoaRthritis: a randomised placebo-controlled trial (SCUlpTOR). NHMRC: National Health and Medical Research Council

Renal Transplant



Renal transplant | Phase 1 clinical trial

Product	CYP-001 (Cymerus™ iPSC-derived MSCs for intravenous infusion)
Indication	Prevention of kidney transplant rejection
Study Design	• ~16 patients to receive CYP-001 after kidney transplantation: cohort 1 (n=3); cohort 2 (n=3); cohort 3 (n=10) • Trial will evaluate safety (all cohorts) and efficacy of MSCs in facilitating reduction of calcineurin inhibitors (anti-rejection medication; Cohort 3)
Study Conduct	• Trial to be conducted and funded by Leiden University Medical Center (LUMC), Netherlands • Regulatory and ethics approvals in place; final trial start-up activities ongoing • Aiming to commence recruitment in Q2 2024
Results	Results of Cohort 1 anticipated in late 2024

Preclinical Programs



Research partnerships

Large body of positive preclinical data generated via R&D partnerships:

- GvHD
- Diabetic wounds
- Critical limb ischaemia
- Organ transplant rejection
- Osteoarthritis
- Respiratory disorders (including asthma, pulmonary fibrosis, acute respiratory distress syndrome)
- Sepsis
- Cardiovascular disorders (including coronary artery disease, myocardial infarction)
- Cytokine release syndrome
- Glioblastoma

Several of these studies have been published in peer-reviewed journals – see cynata.com/science_publications

Studies conducted in partnership with leading research groups worldwide

Monash University
The University of Wisconsin Madison
The University of Sydney
UNSW Sydney
RCSI
University of Massachusetts Amherst
Cell Therapy Manufacturing Cooperative Research Centre
King Faisal Specialist Hospital & Research Centre - Jeddah
Harvard Stem Cell Institute
criticalcare Research Group
SVI St Vincent's Institute Medical Research

cynata therapeutics

Contact Us

Cynata Therapeutics Limited
Level 3, 100 Cubitt Street
Cremorne
Victoria 3121
Australia

info@cynata.com

www.cynata.com

cynatatherapeutics

@cynatastemcells

cynata-therapeutics